English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The selection of the any first line TKI (tyrosine kinase inhibitor) and earlier switch at 3 months to a most powerful TKI based on the insufficient molecular response seem to be the most rational management strategy in chronic myeloid leukemia (CML). The depth of the molecular response and the time to achieve that response are important for the long-term prognosis of the CML patients. This is a key step for the prevention of disease progression in CML.

Key Decision Just After 3 Months Following TKI Initiation in CML: Better and not Difficult